July 7, 2015, the U.S. Food and Drug Administration reviewed and approved ENTRESTO™ (sacubitril/valsartan) tablets to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction. This important news could shift the paradigm in the way heart failure patients will be managed using NT-proBNP in lieu of BNP for patients receiving ENTRESTO™.
In this webinar, we will discuss the analytical and clinical considerations of NT-proBNP testing and the impact of ENTRESTO™ on biomarker testing.
• Describe differences in stability of NT-proBNP and BNP
• Describe the analytical differences between NT-proBNP and BNP assays
• Describe how natriuretic peptides compare in the setting of renal failure
• Describe the mechanism of action of ENTRESTO™ and it’s effect on natriuretic peptides